REVEAL GENOMICS® anuncia la inclusión de su test HER2DX® en las guías clinicas SEOM para cáncer de mama HER2+ en estadios iniciales
REVEAL GENOMICS® Announces Positive Top-Line Results FOR HER2DX® in MEDSIR’S PHERGAIN Trial
REVEAL GENOMICS®´ breakthrough technology enters the liquid biopsy field in Oncology
REVEAL GENOMICS presents the latest HER2DX® data in HER2+ breast cancer at SABCS 2022
HER2DX® recognized by TIME as one of the Best Inventions of 2022
REVEAL GENOMICS® announces positive top-line results for HER2DX® in APT and ATEMPT trials
First clinical impact data of HER2DX® according to two independent studies presented at the SEOM congress
Primeros datos de impacto clínico del HER2DX®️ según dos estudios independientes presentados en el Congreso de la SEOM
Strategic partnership between MEDSIR and REVEAL GENOMICS® for cancer research
Alianza estratégica entre MEDSIR y REVEAL GENOMICS® para investigar contra el cáncer
ESMO 2022: REVEAL GENOMICS®️ presents new validation data of HER2DX®️ in the PerELISA trial
Reveal Genomics y HM Hospitales firman un acuerdo para ofrecer el test genómico HER2DX®️ en su portfolio
Reveal Genomics Announces Research Collaboration in HER2+ Breast Cancer
REVEAL GENOMICS® Markets HER2DX®, The World's First Genomic Test for Personalized HER2+ Breast Cancer Treatment
HER2DX: First genomic test for personalized HER2+ breast cancer treatments
REVEAL GENOMICS APPOINTS PATRICIA VILLAGRASA-GONZÁLEZ CHIEF EXECUTIVE OFFICER
SPIN OFF-REVEAL GENOMICS EMERGES TO DEVELOP INNOVATIVE DIAGNOSTICS TESTS IN ONCOLOGY
